share_log

昆药集团(600422.SH):获得药物临床试验批准通知书

kpc pharmaceuticals, inc. (600422.SH): Received a notice of approval for drug clinical trials.

Gelonghui Finance ·  Nov 22 17:13

On November 22, Gelonghui reported that kpc pharmaceuticals, inc. (600422.SH) announced that the company recently received the Clinical Trial Approval Notification from the National Medical Products Administration for KPC000154 tablets (Notification Numbers: 2024LP02631, 2024LP02632, hereinafter referred to as "the new drug") accepted as a Class 1 new drug, agreeing to carry out relevant clinical trial research. KPC000154 tablets are intended for the treatment of nonalcoholic steatohepatitis (NASH).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment